CD52 and neoplasm: This immunosupportive tumor immune filtrate (increased CD8+ cells and reduced neutrophils) and corresponding reduced tumor size was only observed in the group where mice which received combination treatment with CD5-2 and anti-PD1 and not with either active drug alone.